US congressman resigns over ASX insider trading penny stock scandal

Can you make money in penny stocks?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Headlines are being made in the US today with a Republican Congressman expected to plead guilty to insider trading charges brought by the US securities regulator the SEC.

Making the case unusual is that the micro-cap biotech in question is ASX-listed Innate Immunotherapeutics Limited (ASX: IIL).

Since the scandal it has changed its name to Amplia Therapeutics Limited (ASX: ATX) perhaps in an effort to brush the episode under the carpet. 

According to reports in The Australian newspaper congressman Chris Collins was tipped off over the phone by the Innate Immunotherapeutics CEO that clinical trial results for one of its drugs were negative.

The congressman in possession of the inside information then tipped off his own son who proceeded to sell large amounts of  shares, while tipping off other associates to run for the hills as well. 

When the negative public announcement came the stock tanked 90% lower, with a journalist named Jerry Zremski working as the Washington Bureau chief of The Buffalo News first picking up the story of suspicious activity. 

Mr Zremski even contacted ex-Motley Fool writer and amateur sleuth Sean O'Neill who had also picked up and flagged the suspicious activity as outlined in the excellent article hyperlinked. 

It was lucky for the local regulator ASIC who had the whole affair picked up for it and pursued with gusto by the feared US regulator the SEC. 

For every case of insider trading picked up (in this case Mr Collins' son's greed in selling straight away appears to have given the game away) there are almost certainly dozens or perhaps hundreds of cases that go undetected or unproven.

Out of the around 2,300 companies listed on the local market the majority fall into the small-cap or speculative buckets. 

At this end of the market even if information is not legally 'inside information' different market participants are often acting on different amounts of information. While misinformation or false representations are also a big problem for retail investors to navigate.

Regulation also cannot be relied upon as the principle of 'caveat emptor' persists.

As Julius Caesar once said; "The faultdear Brutus, is not in our stars, but in ourselves.

I would not suggest punting on speculative stocks unless you are a highly-experienced investor well informed on a particular business.  

You can find some of the more popular speccy ASX stocks across all sectors including mining, healthcare, and biotechnology.

Some popular penny stock names with punters looking to get-rich-quick include Paradigm Biopharmaceuticals Ltd (ASX: PAR), Fastbrick Robotics Ltd (ASX: FBR), Avz Minerals Ltd (ASX: AVZ), Benitec Biopharma Ltd (ASX: BLT) and Bionomics Ltd (ASX: BNO). 

Motley Fool contributor Tom Richardson has no position in any of the stocks mentioned.

You can find Tom on Twitter @tommyr345

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Falling yellow arrow with descending wooden bars with the percentage sign written on them.
Share Market News

How much cash will the average mortgage holder save if the RBA cuts interest rates tomorrow?

And how to best redeploy those funds?

Read more »

most shorted shares webjet
Share Market News

These are the 10 most shorted ASX shares

Let's see which shares short sellers are targeting this week.

Read more »

A man in a business suit peers through binoculars as two businesswomen stand beside him looking straight ahead at the camera.
Share Market News

Trump's 9 July tariff deadline looms: 3 ASX 200 companies to watch

It could shape up to be a big week on the tariff front.

Read more »

Business meeting to discuss buy now pay later platform
Broker Notes

Macquarie tips substantial upside for Steadfast shares

Steadfast is a high-quality business at an attractive valuation, according to the broker.

Read more »

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.
Share Market News

5 things to watch on the ASX 200 on Monday

Here's what to expect on the local market on Monday.

Read more »

Three healthcare workers look and point at at medical image
Share Market News

Pro Medicus shares surge 10% to crack $300 as healthcare leads ASX 200 sectors

Pro Medicus shares just keep on going, rising 625% over the past three years.

Read more »

Magnifying glass in front of an open newspaper with paper houses.
Share Market News

How did ASX REITs vs. residential property investment perform in FY25?

We review the share price growth of the largest ASX REITs vs. residential property investment in FY25.

Read more »

A man and woman sit next to each other looking at each other and feeling excited and surprised after reading good news about their shares on a laptop.
Broker Notes

These ASX 200 shares could rise 55% to 65%

Analysts think these shares are dirt cheap at current levels.

Read more »